# Chicago Atlantic BDC, Inc.: financial statements, quarterly

LIEN · Nasdaq · CIK 1843162 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lien.md) · [Financials](/companies/lien/financials.md) · [Filings](/companies/lien/filings.md) · [Insiders](/companies/lien/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lien/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income | $k | [(2,641)](/filings/0001140361-24-045703.md) | [6,413 d](/filings/0001193125-26-115112.md) | [(1,034)](/filings/0001140361-24-025238.md) | [1,293](/filings/0000950170-25-108415.md) | [(165)](/filings/0001193125-25-278786.md) | [7,975 d](/filings/0001193125-26-115112.md) | [7,614](/filings/0001193125-26-222738.md) | [8,584](/filings/0001193125-26-347342.md) | [8,834](/filings/0001193125-25-278786.md) | [8,246 d](/filings/0001193125-26-115112.md) | [8,535](/filings/0001193125-26-222738.md) | [6,064](/filings/0001193125-26-347342.md) |
| Diluted EPS | $ per share | [0.20](/filings/0001140361-24-045703.md) | not reported | [0.08](/filings/0001140361-25-018734.md) | [0.21](/filings/0000950170-25-108415.md) | [(0.03)](/filings/0001193125-25-278786.md) | not reported | [0.33](/filings/0001193125-26-222738.md) | [0.38](/filings/0001193125-26-347342.md) | [0.39](/filings/0001193125-25-278786.md) | not reported | [0.37](/filings/0001193125-26-222738.md) | [0.27](/filings/0001193125-26-347342.md) |
| Basic EPS | $ per share | [0.20](/filings/0001140361-24-045703.md) | not reported | [0.08](/filings/0001140361-25-018734.md) | [0.21](/filings/0000950170-25-108415.md) | [(0.03)](/filings/0001193125-25-278786.md) | not reported | [0.33](/filings/0001193125-26-222738.md) | [0.38](/filings/0001193125-26-347342.md) | [0.39](/filings/0001193125-25-278786.md) | not reported | [0.37](/filings/0001193125-26-222738.md) | [0.27](/filings/0001193125-26-347342.md) |

- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [29.8](/filings/0001140361-23-052491.md) | [32.6](/filings/0001140361-25-011094.md) | [33.2](/filings/0001140361-24-025238.md) | [34.0](/filings/0001140361-24-036447.md) | [30.1](/filings/0001140361-24-045703.md) | [23.9](/filings/0001193125-26-115112.md) | [14.9](/filings/0001140361-25-018734.md) | [13.8](/filings/0000950170-25-108415.md) | [10.5](/filings/0001193125-25-278786.md) | [2.9](/filings/0001193125-26-347342.md) | [3.3](/filings/0001193125-26-222738.md) | [0.9](/filings/0001193125-26-347342.md) |
| Total assets | $m | [89.2](/filings/0001140361-23-052491.md) | [88.6](/filings/0001140361-25-011094.md) | [90.4](/filings/0001140361-24-025238.md) | [90.1](/filings/0001140361-24-036447.md) | [89.3](/filings/0001140361-24-045703.md) | [310](/filings/0001193125-26-115112.md) | [314](/filings/0001140361-25-018734.md) | [332](/filings/0000950170-25-108415.md) | [327](/filings/0001193125-25-278786.md) | [342](/filings/0001193125-26-347342.md) | [373](/filings/0001193125-26-222738.md) | [344](/filings/0001193125-26-347342.md) |
| Total liabilities | $m | [1.8](/filings/0001140361-23-052491.md) | [3.0](/filings/0001140361-25-011094.md) | [5.8](/filings/0001140361-24-025238.md) | [5.8](/filings/0001140361-24-036447.md) | [6.7](/filings/0001140361-24-045703.md) | [8.4](/filings/0001193125-26-115112.md) | [12.7](/filings/0001140361-25-018734.md) | [29.9](/filings/0000950170-25-108415.md) | [24.3](/filings/0001193125-25-278786.md) | [38.6](/filings/0001193125-26-347342.md) | [68.9](/filings/0001193125-26-222738.md) | [41.5](/filings/0001193125-26-347342.md) |
| Shareholders' equity | $m | [87.4](/filings/0001140361-24-045703.md) | [85.6](/filings/0001193125-26-115112.md) | [84.5](/filings/0000950170-25-108415.md) | [84.3](/filings/0001193125-25-278786.md) | [82.5](/filings/0001193125-25-278786.md) | [301](/filings/0001193125-26-347342.md) | [301](/filings/0001193125-26-347342.md) | [302](/filings/0001193125-26-347342.md) | [303](/filings/0001193125-25-278786.md) | [303](/filings/0001193125-26-347342.md) | [304](/filings/0001193125-26-347342.md) | [302](/filings/0001193125-26-347342.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.8 d](/filings/0001140361-24-045703.md) | [7.1 d](/filings/0001193125-26-115112.md) | [2.1](/filings/0001140361-25-018734.md) | [2.5 d](/filings/0000950170-25-108415.md) | [(2.3) d](/filings/0001193125-25-278786.md) | [(7.3) d](/filings/0001193125-26-115112.md) | [(7.3)](/filings/0001193125-26-222738.md) | [1.9 d](/filings/0001193125-26-347342.md) | [(1.4) d](/filings/0001193125-25-278786.md) | [(13.8) d](/filings/0001193125-26-115112.md) | [(20.8)](/filings/0001193125-26-222738.md) | [33.0 d](/filings/0001193125-26-347342.md) |
| Dividends paid | $m | [3.9 d](/filings/0001140361-24-045703.md) | [4.3 d](/filings/0001193125-26-115112.md) | [1.6](/filings/0001140361-25-018734.md) | [1.6 d](/filings/0000950170-25-108415.md) | [1.6 d](/filings/0001193125-25-278786.md) | [7.8 d](/filings/0001193125-26-115112.md) | [0.0](/filings/0001193125-26-222738.md) | [7.8 d](/filings/0001193125-26-347342.md) | [7.8 d](/filings/0001193125-25-278786.md) | [7.8 d](/filings/0001193125-26-115112.md) | [7.8](/filings/0001193125-26-222738.md) | [7.8 d](/filings/0001193125-26-347342.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.2](/filings/0001140361-23-052491.md) | [6.2](/filings/0001140361-24-025238.md) | [6.2](/filings/0001140361-24-036447.md) | [6.2](/filings/0001140361-24-045703.md) | [6.2](/filings/0001140361-25-018734.md) | [6.2](/filings/0000950170-25-108415.md) | [6.2](/filings/0001193125-25-278786.md) | [22.8](/filings/0001193125-26-222738.md) | [22.8](/filings/0001193125-26-347342.md) | [22.8](/filings/0001193125-25-278786.md) | [22.8](/filings/0001193125-26-222738.md) | [22.8](/filings/0001193125-26-347342.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,820,590 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-347342.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.